Announcements Trials
Browse Landscape

Phase

Phase 3 7Phase 2 2Phase 1 2Phase 2/3 1

Status

Completed 7

Sponsor Class

OTHER 33NIH 9NETWORK 7INDUSTRY 7

Study Type

Interventional 7

Sponsor

Cancer Type

Plasma cell 7

Conditions

Multiple Myeloma 7

Interventions

Carboplatin 315Paclitaxel 303Cisplatin 250Docetaxel 238pembrolizumab 230Gemcitabine 214Pemetrexed 158Capecitabine 147Rituximab 144Bevacizumab 142Dexamethasone 125Fluorouracil 121Cyclophosphamide 102Trastuzumab 100Doxorubicin 96Nivolumab 93Prednisone 92Oxaliplatin 90atezolizumab 75Leucovorin 72durvalumab 69130-nm albumin-bound paclitaxel 68Injections 66Lenalidomide 63Irinotecan 62Bortezomib 56Letrozole 54Topotecan 53Fulvestrant 53Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × Thalidomide × Clear all
NCT01539083 2025-02-04

VCAT

Janssen Scientific Affairs, LLC

Phase 3 Completed
256 enrolled 13 charts
Plasma cell

Multiple Myeloma

NCT00689936 2019-11-20

FIRST

Celgene

Phase 3 Completed
1,623 enrolled 56 charts
Plasma cell

Multiple Myeloma

NCT00452569 2019-11-18

OPTIMUM

Celgene

Phase 3 Completed
499 enrolled
Plasma cell

Multiple Myeloma

NCT00097981 2017-04-07

A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3 Completed
225 enrolled 14 charts
Plasma cell

Multiple Myeloma

NCT00057564 2015-09-11

A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma

Celgene

Phase 3 Completed
470 enrolled
Plasma cell

Multiple Myeloma

NCT00507416 2014-05-01

UPFRONT

Millennium Pharmaceuticals, Inc.

Phase 3 Completed
502 enrolled 17 charts
Plasma cell

Multiple Myeloma

NCT00934154 2013-08-15

Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma

Erkim Ilac A.S.

Phase 3 Completed
122 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡